Recovery From COVID-19 in Multiple Sclerosis

  1. Afagh Garjani
  2. Rodden M. Middleton
  3. Richard Nicholas
  4. Nikos Evangelou

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1212/nxi.0000000000001118
  2. ScreenIT

    SciScore for 10.1101/2021.06.25.21259256: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: Ethical approval for UKMSR studies was obtained from Southwest-Central Bristol Research Ethics Committee (16/SW/0194) and all participant provided informed consent, online.
    Consent: Ethical approval for UKMSR studies was obtained from Southwest-Central Bristol Research Ethics Committee (16/SW/0194) and all participant provided informed consent, online.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    13 Statistical Analysis: Data were analysed using IBM SPSS Statistics for Windows, version 26 (IBM Corp.,
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Although the lack of a direct control group, for example recording any new symptoms in people with MS without COVID-19, is a limitation of this study, we feel that it is unlikely to affect these results. These findings in a study population comprised of mostly non-hospitalised people with MS and COVID-19 highlight previous observations that people with COVID-19 treated in the community can also experience prolonged symptoms of COVID-19.2,18 An association between pre-COVID-19 physical disability in people with MS and adverse acute COVID-19 outcomes has been previously reported.19 Our study shows that higher levels of physical disability predispose them to long COVID as well. It is possible that long-lasting symptoms of COVID-19 in populations with asthma or MS be a deterioration of their pre-existing condition triggered by the infection rather than persistent new symptoms of COVID-19? It is known that respiratory infections can trigger asthma exacerbations,20 and we have previously shown that COVID-19 can lead to MS exacerbations.21 New or worsening fatigue was the most common persisting symptom in our population followed by lower respiratory tract symptoms, a pattern similar to the general population.2,3 Fatigue, however, is also prevalent in MS.4 Further research is needed to understand what is long COVID and whether it presents with different symptom patterns in populations with other pre-existing disorders. We think these observations are important as healthcare services ...

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04354519RecruitingThe United Kingdom Multiple Sclerosis Register Covid-19 Subs…

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.06.25.21259256v1 on medRxiv